Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 movers: Lloyds declines as state investment vehicle lowers stake, miners lower

Mon, 01st Jun 2015 13:49

UK shares were trading lower on Monday afternoon, ahead of a raft of US economic data, as weakness in mining, oil and insurance stocks outweighed gains made in the real estate, travel and electronics sectors.As of 15:30 BST, the FTSE 100 was trading 0.23% lower at 6,988.Lloyds registered losses as UK Financial Investments, the state investment vehicle, lowered its stake to 18.99% from the 19.93% it held on 12 May. The move follows continued market speculation surrounding the timing public share-selling, with the aim of returning the lender wholly to private ownership, possibly as early as September.Morrison dipped ahead of this week's annual meeting, as investors are expected to object to former chief executive Dalton Phillips's substantial payoff. The company is also at risk of being removed from the FTSE 100 altogether, to be replaced by satellite communications group Inmarsat.Prudential was also weaker as it appointed Barry Stowe as chairman and chief executive of its North American business.Miners Fresnillo, Anglo American and Glencore were in the red following weak manufacturing data from China, the world's biggest metals consumer. Oil giants Weir Group and Shell also declined, as oil prices retreated from last week's highs.Shell was also hit with allegations that it tried to use its connections with the Science Museum to influence the presentation of its Climate Change programme. A leaked internal email expressed concerns that a particular part of the project sponsored by the company "creates an opportunity for NGOs [non-governmental organisations] to talk about some of the issues that concern them around Shell's operations".Astrazeneca was boosted by positive takeaways from the annual meeting of the American Society of Clinical Oncology, during which the company presented preliminary data for one of its lung cancer drugs.WPP was trading higher, despite reports that it could face opposition from shareholders at its annual meeting on 9 June over chief executive Martin Sorrell's £43m pay award for 2014. Glass Lewis and Institutional Shareholder Services (ISS), which advise investors that own about a quarter of the equities on the UK stock market, have both raised concerns about the 40% increase, according to The Financial Times.RisersAshtead Group (AHT) 1,155.00p +3.12%Dixons Carphone (DC.) 485.40p +2.10%International Consolidated Airlines Group SA (CDI) (IAG) 564.00p +1.81%British Land Company (BLND) 877.00p +1.74%St James's Place (STJ) 926.00p +1.59%Intertek Group (ITRK) 2,540.00p +1.56%InterContinental Hotels Group (IHG) 2,781.00p +1.46%Land Securities Group (LAND) 1,332.00p +1.45%Lloyds Banking Group (LLOY) 88.95p +1.34%Taylor Wimpey (TW.) 185.80p +1.25%FallersWeir Group (WEIR) 1,978.00p -2.27%Standard Chartered (STAN) 1,033.00p -1.24%Glencore (GLEN) 284.65p -1.15%Royal Dutch Shell 'B' (RDSB) 1,956.00p -0.89%Anglo American (AAL) 1,017.00p -0.88%Imperial Tobacco Group (IMT) 3,341.00p -0.86%Kingfisher (KGF) 366.90p -0.84%Barclays (BARC) 268.10p -0.70%Aggreko (AGK) 1,597.00p -0.68%Mondi (MNDI) 1,466.00p -0.68%
More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.